Shalby returns to profit in Q4 FY26, MedTech EBITDA turns positive

2 min read     Updated on 03 Jun 2026, 03:01 AM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Shalby Limited returned to profitability in Q4 FY26 with a net profit of ₹18.5 crores, reversing a loss of ₹12.2 crores in the prior year. Revenue increased by 9.4% to ₹295.5 crores, supported by growth in hospitals and MedTech, while EBITDA margins improved to 12.7%. The MedTech segment turned EBITDA positive at ₹3.7 crores, and the full-year net profit reached ₹34.7 crores.

powered bylight_fuzz_icon
41449434

*this image is generated using AI for illustrative purposes only.

Shalby Limited returned to profitability in the fourth quarter of FY26, reporting a consolidated net profit of ₹18.5 crores against a loss of ₹12.2 crores in the corresponding period of the previous year. The company's revenue from operations rose to ₹295.5 crores year-on-year, registering a growth of 9.4%, driven by growth across its hospital and MedTech verticals. Operational efficiency improved notably, with EBITDA growing to ₹37.4 crores from ₹26.2 crores in Q4 FY25, and the EBITDA margin expanding to 12.7% from 9.7%. For the full year FY26, consolidated revenue grew to ₹1,168.2 crores, while net profit stood at ₹34.7 crores.

Consolidated Performance Highlights

The financial turnaround was supported by robust performance in the standalone business and the implant manufacturing segment. The adoption of the new tax regime during the period influenced the profitability metrics, reducing the tax rate to 25% from 35%. The table below summarises the key consolidated financial metrics for the quarter:

Metric Q4 FY25 Q4 FY26
Revenue ₹270.2 crores ₹295.5 crores
EBITDA ₹26.2 crores ₹37.4 crores
EBITDA Margin 9.7% 12.7%
Net Profit / (Loss) ₹(12.2) crores ₹18.5 crores

Segment and Operational Performance

Shalby Hospitals, Pharma & Franchise contributed 79.16% to the consolidated revenue at ₹2,339.5 million, while Shalby MedTech recorded a 45% year-on-year jump in revenue to ₹40 crores. The standalone entity reported a 7.6% increase in quarterly revenue to ₹230.4 crores, with a net profit of ₹53.7 crores. On the operational front, the hospital business saw a rise in surgery counts, with Arthroplasty procedures growing by 15.4% year-on-year to over 2,650 surgeries in Q4 FY26.

MedTech and International Business

Shalby MedTech delivered a significant turnaround in profitability, reporting a positive EBITDA of ₹3.7 crores compared to a loss of ₹9.3 crores in Q4 FY25. For the full year FY26, the segment achieved a positive EBITDA of ₹6.7 crores against a loss of ₹19.2 crores in FY25. The international business faced headwinds due to geopolitical situations impacting patient inflows to the Gurugram unit, though growth in African and CIS countries provided some offset. The group completed 70 transplants during FY26, including 51 kidney and 19 liver transplants.

Statutory Auditor's Report

M/s. T R Chadha & Co LLP, Chartered Accountants, issued an unmodified opinion on the standalone and consolidated financial results. The report confirmed that the statements give a true and fair view of the financial position and performance of the company in conformity with applicable accounting standards.

Regulatory Disclosure

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted the copies of the advertisement published on May 29, 2026, in the Financial Express for the audited financial results. The results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 27, 2026. A transcript of the earnings conference call held on May 29, 2026, was also submitted to the exchanges.

Historical Stock Returns for Shalby

1 Day5 Days1 Month6 Months1 Year5 Years
+0.31%+0.31%+0.71%-14.48%-4.69%+7.36%

Can Shalby maintain the current 12.7% EBITDA margin in the coming quarters given the operational efficiency improvements?

What is the growth strategy for the MedTech vertical following its return to positive EBITDA?

How will the company mitigate geopolitical headwinds affecting patient inflows to the Gurugram unit in the next fiscal year?

Shalby corrects Cost Auditor appointment to S A & Associates for FY 2026-27

1 min read     Updated on 29 May 2026, 08:55 AM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Shalby Limited corrected a typographical error regarding the appointment of its Cost Auditor for the financial year 2026-27. The company confirmed that S A & Associates, based in Ahmedabad, has been appointed to audit the cost accounts of the company. This correction follows the Board meeting held on May 27, 2026, where the appointment was originally approved based on the recommendation of the Audit Committee.

powered bylight_fuzz_icon
41502074

*this image is generated using AI for illustrative purposes only.

Shalby Limited has corrected a typographical error regarding the appointment of its Cost Auditor for the financial year 2026-27. The company confirmed that S A & Associates, based in Ahmedabad, has been appointed to audit the cost accounts of the company. This correction follows the Board meeting held on May 27, 2026, where the appointment was originally approved based on the recommendation of the Audit Committee.

The disclosure was made to the National Stock Exchange of India Ltd and BSE Limited under Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The earlier announcement had erroneously named M/s. Borad Sanjay B & Associates as the appointed firm.

Details of Appointment

The corrected filing provides the specific details regarding the new Cost Auditor and the terms of the engagement.

Particulars Details
Reason for change Appointment of S A & Associates, Ahmedabad Firm Regn. No. 000347 as Cost Auditor for FY 2026-27
Date of Appointment May 27, 2026
Terms of appointment Approved by the Board based on Audit Committee recommendation for Audit of Cost Accounts for FY 2026-27

Profile of S A & Associates

S A & Associates is a firm of Practicing Cost Accountants registered with the Institute of Cost Accountants of India under Firm Registration No. 000347. The Ahmedabad-based firm specializes in cost auditing, cost records compliance, cost and management consultancy, and process and operational improvements.

The firm is led by FCMA Sanjay B. Borad, a professional with qualifications including Cost & Management Accountant (CMA), Company Secretary (CS), MBA (Finance), Insolvency Professional (IP), and Independent Director (ID). The firm possesses over two decades of experience handling cost audit and advisory assignments across more than 15 industries, including Metal, FMCG, Chemicals, Engineering, Automotive Components, Textiles, Electronics, Construction, Healthcare, Plastics, and Infrastructure.

Historical Stock Returns for Shalby

1 Day5 Days1 Month6 Months1 Year5 Years
+0.31%+0.31%+0.71%-14.48%-4.69%+7.36%

How might the appointment of a firm with extensive cross-industry experience influence Shalby Limited's operational cost efficiencies?

Will the new Cost Auditor's focus on process improvements lead to strategic shifts in Shalby's healthcare cost management?

Could this change in auditor oversight signal a broader review of Shalby's internal compliance and governance frameworks?

More News on Shalby

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:-4.69%